EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis

Objective To develop evidence-based recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Methods A task force comprising 7 rheumatologists, 15 other healthcare professionals and 3 patients was established. Following a systematic literature review performed to inform the recommendations, statements were formulated, discussed…

Read the full article here

Source: Annals of the Rheumatic Diseases

Categories: Latest Headlines, Rheumatology

Tags: SLE, SSc

Tweets with this article

ARD & RMD Open

EULAR recommendations for the non-pharmacological management of #SLE and #SSc 📕 patient education and self-management 🚭 cessation of smoking ❄️ avoidance of cold exposure 🤸 physical exercise and more... Read the full recommendations here 👇 https://t.co/PPmOMtEMeb

Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases

Due to optimised treatment strategies and the availability of new therapies during the last decades, formerly devastating chronic inflammatory diseases such as rheumatoid arthritis or…

ARD & RMD Open May 4, 2024

Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS

Objectives Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib…

ARD & RMD Open May 3, 2024

Is tooth extraction as proxy for periodontal disease related to the development of RA? Lessons from a longitudinal study in the at-risk stage of clinically suspect arthralgia

Emerging evidence points to the involvement of periodontal disease (PD) in the pathogenesis of rheumatoid arthritis (RA), especially in anti-citrullinated protein antibodies (ACPA)-positive RA. The…

ARD & RMD Open May 2, 2024

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)

Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed…

ARD & RMD Open May 1, 2024

Vascular disease persistence in giant cell arteritis: are stromal cells neglected?

Giant cell arteritis (GCA), the most common systemic vasculitis, is characterised by aberrant interactions between infiltrating and resident cells of the vessel wall. Ageing and…

ARD & RMD Open April 30, 2024

Managing Systemic Lupus Erythematosus: the latest EULAR recommendations | ARD Podcast

This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE). ARD’s Social Media Advisor, Professor Laura…

ARD & RMD Open April 29, 2024

bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease

Introduction AA amyloidosis (AA) can be the consequence of any chronic inflammatory disease. AA is associated with chronic inflammatory diseases (cid+AA), autoinflammatory syndromes (auto+AA) or…

ARD & RMD Open April 26, 2024

Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS

ARD & RMD Open April 25, 2024

What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases

Messenger RNA (mRNA) vaccines as a novel vaccine platform offer new tools to effectively combat both emerging and existing pathogens which were previously not possible.…

ARD & RMD Open April 24, 2024

Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne

Objectives To study the molecular pathogenesis of PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome, a debilitating hereditary autoinflammatory disease caused by dominant mutation in…

ARD & RMD Open April 22, 2024

Related Articles